A phase 1 safety, pharmacokinetic and pharmacodynamic study of AG-024322, an inhibitor of cyclin-dependent kinase 1, 2 and 4, administered intravenously daily for 5 days every 3 weeks to patients with advanced cancer
Phase of Trial: Phase I
Latest Information Update: 15 Aug 2007
At a glance
- Drugs AG 024322 (Primary)
- Indications Diffuse lymphoma; Follicular lymphoma; Solid tumours
- Focus Adverse reactions
- 15 Aug 2007 Status change from recruiting to discontinued.
- 03 Nov 2005 New trial record.